FI102517B1 - Menetelmä terapeuttisesti käyttökelpoisen immunokonjugaatin valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen immunokonjugaatin valmistamiseksi

Info

Publication number
FI102517B1
FI102517B1 FI910049A FI910049A FI102517B1 FI 102517 B1 FI102517 B1 FI 102517B1 FI 910049 A FI910049 A FI 910049A FI 910049 A FI910049 A FI 910049A FI 102517 B1 FI102517 B1 FI 102517B1
Authority
FI
Finland
Prior art keywords
preparing
therapeutically useful
useful immunoconjugate
immunoconjugate
therapeutically
Prior art date
Application number
FI910049A
Other languages
English (en)
Swedish (sv)
Other versions
FI910049A0 (fi
FI102517B (fi
Inventor
Michael G Rosenblum
Renato Dulbecco
W Ross Allen
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of FI910049A0 publication Critical patent/FI910049A0/fi
Application granted granted Critical
Publication of FI102517B1 publication Critical patent/FI102517B1/fi
Publication of FI102517B publication Critical patent/FI102517B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
FI910049A 1988-07-07 1991-01-04 Menetelmä terapeuttisesti käyttökelpoisen immunokonjugaatin valmistami seksi FI102517B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21659588A 1988-07-07 1988-07-07
US21659588 1988-07-07
US8902919 1989-06-29
PCT/US1989/002919 WO1990000405A1 (en) 1988-07-07 1989-06-29 Immunoconjugates for cancer diagnosis and therapy

Publications (3)

Publication Number Publication Date
FI910049A0 FI910049A0 (fi) 1991-01-04
FI102517B1 true FI102517B1 (fi) 1998-12-31
FI102517B FI102517B (fi) 1998-12-31

Family

ID=22807704

Family Applications (1)

Application Number Title Priority Date Filing Date
FI910049A FI102517B (fi) 1988-07-07 1991-01-04 Menetelmä terapeuttisesti käyttökelpoisen immunokonjugaatin valmistami seksi

Country Status (18)

Country Link
US (1) US6669938B1 (fi)
EP (2) EP0423228B1 (fi)
JP (1) JP2756329B2 (fi)
KR (1) KR0152272B1 (fi)
AU (1) AU636113B2 (fi)
CA (1) CA1336497C (fi)
DE (1) DE68912334T2 (fi)
DK (1) DK175835B1 (fi)
ES (1) ES2059759T3 (fi)
FI (1) FI102517B (fi)
HK (1) HK1006676A1 (fi)
IE (1) IE62463B1 (fi)
IL (1) IL90688A (fi)
NO (1) NO303122B1 (fi)
NZ (1) NZ229652A (fi)
PT (1) PT91075B (fi)
WO (1) WO1990000405A1 (fi)
ZA (1) ZA894665B (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
IL97776A (en) * 1990-04-19 2000-10-31 Res Dev Foundation Composition comprising a conjugate of a ZME antibody and a biological response modifier
IE912716A1 (en) * 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
IT1286663B1 (it) * 1996-06-27 1998-07-15 Ministero Uni Ricerca Scient E Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
PT1366067E (pt) 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
EP1414471B1 (en) 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
HU229098B1 (hu) 2001-12-04 2013-07-29 Merck Patent Gmbh Megváltoztatott szelektivitású immuncitokinek
CN1662254A (zh) * 2002-05-03 2005-08-31 雷文生物技术公司 Alcam和alcam调制剂
EP1572170A4 (en) * 2002-06-12 2007-02-28 Res Dev Foundation IMMUNOTOXIN AS THERAPEUTIC AGENT AND USES THEREOF
BRPI0317376B8 (pt) 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2595904A1 (en) * 2005-02-01 2006-08-10 Research Development Foundation Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
WO2008031767A1 (en) * 2006-09-12 2008-03-20 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Cell culture of keratinocytes under non-differentiating conditions
GB0718045D0 (en) * 2007-09-14 2007-10-24 Peptcell Ltd Pharmaceutical compound
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
US4440747A (en) 1980-09-30 1984-04-03 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease
US4520226A (en) 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
GB2131830A (en) 1982-12-10 1984-06-27 Ludwig Inst Cancer Res Monoclonal antibody for use against breast cancer
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DK423483A (da) 1983-09-16 1985-03-17 Nordisk Laederforskningsraad Fremgangsmaade til maerkning af huder, skind og lignende arkformige materialer
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
DE3408463C2 (de) * 1984-03-08 1987-02-26 Giulini Chemie Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung einer aluminium- und magnesiumhaltigen Verbindung der Formel Al↓5↓Mg↓1↓↓0↓ (OH)↓3↓↓1↓ (SO↓4↓)↓2↓ . x H↓2↓O
CA1306428C (en) * 1984-12-05 1992-08-18 Christine A. White Monoclonal antibody specific for a mammary tumor cell surface antigen
WO1986005098A1 (en) * 1985-03-04 1986-09-12 Dana-Farber Cancer Institute, Inc. Immunotoxin and method of making
JP2524586B2 (ja) * 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
JPS6220909A (ja) 1985-07-17 1987-01-29 株式会社井上ジャパックス研究所 パイプ等の接合方法
FR2587332B1 (fr) 1985-09-19 1989-02-17 Rhone Poulenc Spec Chim Procede de chloration selective de composes phenoliques
CA1287578C (en) 1985-12-06 1991-08-13 Michael J. Bjorn Anti-human ovarian cancer immunotoxins and methods of use thereof
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
EP0256471A3 (en) 1986-08-15 1989-10-25 Xoma Corporation Cytotoxic conjugates for cancer therapy
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
DE68912334D1 (de) 1994-02-24
EP0350230A3 (en) 1990-12-12
EP0423228B1 (en) 1994-01-12
NZ229652A (en) 1991-08-27
PT91075A (pt) 1990-02-08
WO1990000405A1 (en) 1990-01-25
IL90688A0 (en) 1990-01-18
NO303122B1 (no) 1998-06-02
NO910031D0 (no) 1991-01-04
AU636113B2 (en) 1993-04-22
EP0423228A4 (en) 1991-07-17
AU3976189A (en) 1990-02-05
HK1006676A1 (en) 1999-03-12
EP0350230B1 (en) 1993-09-15
FI910049A0 (fi) 1991-01-04
IL90688A (en) 1995-03-30
IE62463B1 (en) 1995-02-08
KR0152272B1 (ko) 1998-10-15
DE68912334T2 (de) 1994-05-05
FI102517B (fi) 1998-12-31
ZA894665B (en) 1990-04-25
EP0350230A2 (en) 1990-01-10
DK1091A (da) 1991-01-04
NO910031L (no) 1991-01-04
CA1336497C (en) 1995-08-01
DK1091D0 (da) 1991-01-04
IE891970L (en) 1990-01-07
JP2756329B2 (ja) 1998-05-25
JPH04500510A (ja) 1992-01-30
PT91075B (pt) 1995-01-31
ES2059759T3 (es) 1994-11-16
DK175835B1 (da) 2005-03-21
US6669938B1 (en) 2003-12-30
EP0423228A1 (en) 1991-04-24
KR900701321A (ko) 1990-12-01

Similar Documents

Publication Publication Date Title
FI102517B1 (fi) Menetelmä terapeuttisesti käyttökelpoisen immunokonjugaatin valmistamiseksi
FI104170B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-amidopyratsolijohdannaisten valmistamiseksi
FI904654A0 (fi) Menetelmä valmistaa metallikiinnitin
FI882046A (fi) Menetelmä laatikkomaisen rakenteen valmistamiseksi
NO176758C (no) Analogifremgangsmåte for fremstilling av terapeutiske anvendbare tetrazolyl-bifenylylmetyl-pyrimidiner
FI98924B (fi) Menetelmä pigmentin valmistamiseksi
FI890286A (fi) Menetelmä terapeuttisesti käyttökelpoisten dideoksikarbosyklisten nukleosidianalogien valmistamiseksi
FI884182A0 (fi) Menetelmä lignoselluoosaa sisältävän materiaalin kuiduttamiseksi
FI94752C (fi) Menetelmä terapeuttisesti käyttökelpoisten propenonioksiimieettereiden valmistamiseksi
FI906407A0 (fi) Menetelmä kestävän teräksen valmistamiseksi
FI88172C (fi) Foerfarande foer framstaellning av ett omdispergerbart plastmjoel
FI883672A (fi) Menetelmä terapeuttisesti käyttökelpoisten aminoalkoksifenyylijohdannaisten valmistamiseksi
FI884983A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten LL-E33288 kompleksi-disulfidianalogien valmistamiseksi
FI893003A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
FI911420A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten yhdisteiden valmistamiseksi
FI880842A (fi) Menetelmä kiteisen kefeemisulfaatin valmistamiseksi
FI92064C (fi) Menetelmä terapeuttisesti käyttökelpoisten N-bentsopyranyylilaktaamien valmistamiseksi
FI881158A (fi) Menetelmä terapeuttisesti käyttökelpoisen immunoglobuliinikonjugaatin valmistamiseksi
FI98459B (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-etano-2,3,4,5-1H-2-bentsatsepin-7-olikarbamaattijohdannaisten valmistamiseksi
FI913554A (fi) Menetelmä stabiloidun farmaseuttisen koostumuksen valmistamiseksi
NO174200C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-imino-6-polyfluoralkoksybenzotiazol-forbindelser
FI911701A (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-substituoitujen alkyyli-3-karboksikarbapeneemien valmistamiseksi
FI884473A (fi) Menetelmä terapeuttisesti käyttökelpoisten fenoksialkyylipyrokatekolijohdannaisten valmistamiseksi
PT87672A (pt) Process for preparing a pharmaceutical composition
FI910967A0 (fi) Menetelmä bisfenoli A:n valmistamiseksi